Many recent studies have brought into question the approval process that the FDA uses for new drugs. A great number of them get pulled from the market within months of being approved, and in most cases its due to insufficient testing time or lack of transparency in the first place. The latest fiasco involves a cardiac drug called Multaq that is designed to help control atrial fibrillation, a common type of irregular heartbeat. While the media downplays the results, the study shows that if you suffer from atrial fibrillation youre actually better off if you dont take any drugs for it at all.
The study consisted of 3,000 patients over age 65, and 32 of the ones taking Multaq died from heart attack or stroke while only 14 members of the placebo group met a similar fate. More than twice the number of patients on the drug died than those just taking a sugar pill for a heart condition. You would quite literally be better off popping a tic-tac twice a day than taking this drug.
Multaq was approved in 2009, and even after these findings the FDA isnt ordering if off the market. Instead, they are just recommending patients to talk to their doctors about their doubled risk of death. The entire process for drug approval should be reevaluated, and major changes put in place. The Journal of the American Medical Association published a study that found that only half of the new drugs introduced to the market in the last 10 years had proper data prior to approval, yet were ushered in anyway.